09:50 AM EST - Valeant Pharmaceuticals International, Inc. : announced that it has entered into a definitive agreement under which Valeant will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, Clindagel, and BenzEFoam. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $0.49 at $151.62.
